AIM: To evaluate the downstaging rates in hepatitis C virus-patients with hepatocellular carcinoma(HCC), treated with degradable starch microspheres transcatheter arterial chemoembolization(DSM-TACE), to reach new-Mil...AIM: To evaluate the downstaging rates in hepatitis C virus-patients with hepatocellular carcinoma(HCC), treated with degradable starch microspheres transcatheter arterial chemoembolization(DSM-TACE), to reach new-Milan-criteria(nM C) for transplantation. METHODS: This study was approved by the Ethics Committee of our institution. From September 2013 to March 2014 eight patients(5 men and 3 women) with liver cirrhosis and multinodular HCC, that did not meet n MC at baseline, were enrolled in this study. Patients who received any other type of treatment such as termal ablation or percutaneous ethanol injection were excluded. DSM-TACE was performed in all patients using Embo Cept? S and doxorubicin. Baseline and follow-up computed tomography or magnetic resonance imaging was assessed measuring the longest enhancing axial dimension of each tumor according to the modified Response Evaluation Criteria In Solid Tumors measure-ments, and medical records were reviewed.RESULTS: DSM-TACE was successfully performed in all patients without major complication. We treated 35 lesions(mean 4.3 per patient). Six of eight patients(75%) had their HCC downstaged to meet nM C. Every patient whose disease was downstaged eventually underwent transplantation. The six patients who received transplant were still living at the time of this writing, without recurrence of HCC. Baseline age(P = 0.25), Model for End-stage Liver Disease score(P = 0. 77), and α-fetoprotein level(P = 1.00) were similar between patients with and without downstaged HCC. CONCLUSION: DSM-TACE represents a safely and effective treatment option with similar safety and efficacy of conventional chemoembolization and could be successfully performed also for downstaging disease in patients without n MC, allowing them to reach liver transplantation.展开更多
研究反相微乳法合成淀粉微球,采用环氧氯丙烷活化淀粉微球,考察了活化过程中的影响因素,确定了活化的最佳优化条件;再将制备的肝特异性脂蛋白(liver specific lipoprotein,LSP)抗体与淀粉微球交联,得到免疫淀粉微球;阐述了免疫淀粉微球...研究反相微乳法合成淀粉微球,采用环氧氯丙烷活化淀粉微球,考察了活化过程中的影响因素,确定了活化的最佳优化条件;再将制备的肝特异性脂蛋白(liver specific lipoprotein,LSP)抗体与淀粉微球交联,得到免疫淀粉微球;阐述了免疫淀粉微球对抗原肝特异性脂蛋白(LSP)的结合特性。经测定单位淀粉微球交联LSP抗体的量为7.7 mg/g,单位免疫淀粉微球结合LSP的量为0.5 mg/g,表明被交联的抗体保持了较高的生物活性。展开更多
目的：观察无肝期前输注羟乙基淀粉（130/0.4）溶液对原位肝移植术后急性肺损伤的影响。方法：90例ASAⅡ-Ⅳ级晚期肝病患者随机分为3组,分别于麻醉诱导后无肝期前经中心静脉以10 m L/（kg·h）的速度输注羟乙基淀粉（130/0.4）溶液...目的：观察无肝期前输注羟乙基淀粉（130/0.4）溶液对原位肝移植术后急性肺损伤的影响。方法：90例ASAⅡ-Ⅳ级晚期肝病患者随机分为3组,分别于麻醉诱导后无肝期前经中心静脉以10 m L/（kg·h）的速度输注羟乙基淀粉（130/0.4）溶液（H组）、琥珀酰明胶溶液（S组）、生理盐水（N组）,剂量为20m L/kg。所有患者术后随访至术后28 d或患者死亡。记录并比较各组患者术后呼吸机支持时间、ICU停留时间、急性肺损伤（ALI）发生率、住院时间和术后28 d生存率。结果：H组术后呼吸支持时间为（20.4±4.7）h,短于S组的（24.8±7.1）h和N组的（27.1±7.7）h,差异具有统计学意义（P〈0.01）;H组ICU停留时间为（5.7±1.3）d,明显少于S组的（7.0±1.9）d和N组的（8.1±1.7）d,差异具有统计学意义（P〈0.05）。H组术后急性肺损伤发生率为16.7%,而S组和N组分别为39.3%和48.3%,差异具有统计学意义（P〈0.05）。住院时间、术后28 d生存率在各组间均没有明显差异。结论：与琥珀酰明胶溶液或生理盐水相比,羟乙基淀粉（130/0.4）溶液能有效减轻原位肝移植术后急性肺损伤。展开更多
文摘AIM: To evaluate the downstaging rates in hepatitis C virus-patients with hepatocellular carcinoma(HCC), treated with degradable starch microspheres transcatheter arterial chemoembolization(DSM-TACE), to reach new-Milan-criteria(nM C) for transplantation. METHODS: This study was approved by the Ethics Committee of our institution. From September 2013 to March 2014 eight patients(5 men and 3 women) with liver cirrhosis and multinodular HCC, that did not meet n MC at baseline, were enrolled in this study. Patients who received any other type of treatment such as termal ablation or percutaneous ethanol injection were excluded. DSM-TACE was performed in all patients using Embo Cept? S and doxorubicin. Baseline and follow-up computed tomography or magnetic resonance imaging was assessed measuring the longest enhancing axial dimension of each tumor according to the modified Response Evaluation Criteria In Solid Tumors measure-ments, and medical records were reviewed.RESULTS: DSM-TACE was successfully performed in all patients without major complication. We treated 35 lesions(mean 4.3 per patient). Six of eight patients(75%) had their HCC downstaged to meet nM C. Every patient whose disease was downstaged eventually underwent transplantation. The six patients who received transplant were still living at the time of this writing, without recurrence of HCC. Baseline age(P = 0.25), Model for End-stage Liver Disease score(P = 0. 77), and α-fetoprotein level(P = 1.00) were similar between patients with and without downstaged HCC. CONCLUSION: DSM-TACE represents a safely and effective treatment option with similar safety and efficacy of conventional chemoembolization and could be successfully performed also for downstaging disease in patients without n MC, allowing them to reach liver transplantation.
文摘研究反相微乳法合成淀粉微球,采用环氧氯丙烷活化淀粉微球,考察了活化过程中的影响因素,确定了活化的最佳优化条件;再将制备的肝特异性脂蛋白(liver specific lipoprotein,LSP)抗体与淀粉微球交联,得到免疫淀粉微球;阐述了免疫淀粉微球对抗原肝特异性脂蛋白(LSP)的结合特性。经测定单位淀粉微球交联LSP抗体的量为7.7 mg/g,单位免疫淀粉微球结合LSP的量为0.5 mg/g,表明被交联的抗体保持了较高的生物活性。
